Silence Therapeutics Shareholders Approve Delisting From AIM
Silence Therapeutics Shareholders Approve Delisting From AIM
By Joe Hoppe
Silence Therapeutics PLC said Monday that its shareholders voted to approve the cancellation of its listing on London's junior AIM, keeping a single listing on New York's Nasdaq.
The medical company said on Oct. 15 that it would seek shareholder approval to delist, adding that the move would enhance liquidity in its American Depositary Shares and increase U.S. investors' willingness to invest in the company.
The last day of trading is expected to be Nov. 29.
Write to Joe Hoppe at joseph.hoppe@wsj.com
By Joe Hoppe
喬·霍普(Joe Hoppe)著
Silence Therapeutics PLC said Monday that its shareholders voted to approve the cancellation of its listing on London's junior AIM, keeping a single listing on New York's Nasdaq.
沉默治療公司週一表示，其股東投票批准取消其在倫敦初級AIM的上市，保留在紐約納斯達克(Nasdaq)的單一上市。
The medical company said on Oct. 15 that it would seek shareholder approval to delist, adding that the move would enhance liquidity in its American Depositary Shares and increase U.S. investors' willingness to invest in the company.
這家醫療公司10月15日表示，將尋求股東批准退市，並稱此舉將增強其美國存托股份的流動性，並提高美國投資者投資該公司的意願。
The last day of trading is expected to be Nov. 29.
最後一個交易日預計是11月29日。
Write to Joe Hoppe at joseph.hoppe@wsj.com
寫信給喬·霍普(joseph.hop pe@wsj.com)
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧